PHASE-II TRIAL 4'-DEOXYDOXORUBICIN IN PATIENTS WITH ADVANCED BREAST-CANCER

  • 1 January 1985
    • journal article
    • research article
    • Vol. 69  (11) , 1319-1320
Abstract
4''-Deoxydroxorubicin (25 mg/m2 iv every 3 weeks) was evaluated in 20 patients with advanced breast cancer. The patients had good performance status and had not been heavily pretreated. Although all patients experienced leukopenia, nor major therapeutic responses were observed. Nonhematologic toxicity was mild. Further evaluation of 4''-deoxydoxorubicin at this dose and schedule is not warranted in patients with advanced breast cancer.